Genome-wide association study identifies variants in the ABO locus associated with susceptibility to pancreatic cancer

Laufey Amundadottir; Peter Kraft; Rachael Z. Stolzenberg-Solomon; Charles S. Fuchs; Gloria M. Petersen; Alan A. Arslan; H. Bas Bueno-De-Mesquita; Myron Gross; Kathy Helzlsouer; Eric J. Jacobs; Andrea LaCroix; Wei Zheng; Demetrius Albanes; William Bamlet; Christine D. Berg; Franco Berrino; Sheila Bingham; Julie E. Buring; Paige M. Bracci; Federico Canzian; Françoise Clavel-Chapelon; Sandra Clipp; Michelle Cotterchio; Mariza De Andrade; Eric J. Duell; John W. Fox; Steven Gallinger; J. Michael Gaziano; Edward L. Giovannucci; Michael Goggins; Carlos A. González; Göran Hallmans; Susan E. Hankinson; Manal Hassan; Elizabeth A. Holly; David J. Hunter; Amy Hutchinson; Rebecca Jackson; Kevin B. Jacobs; Mazda Jenab; Rudolf Kaaks; Alison P. Klein; Charles Kooperberg; Robert C. Kurtz; Donghui Li; Shannon M. Lynch; Margaret Mandelson; Robert R. McWilliams; Julie B. Mendelsohn; Dominique S. Michaud; Sara H. Olson; Kim Overvad; Alpa V. Patel; Petra H.M. Peeters; Aleksandar Rajkovic; Elio Riboli; Harvey A. Risch; Xiao Ou Shu; Gilles Thomas; Geoffrey S. Tobias; Dimitrios Trichopoulos; Stephen K. Van Den Eeden; Jarmo Virtamo; Jean Wactawski-Wende; Brian M. Wolpin; Herbert Yu; Kai Yu; Anne Zeleniuch-Jacquotte; Stephen J. Chanock; Patricia Hartge; Robert N. Hoover

doi:10.1038/ng.429

Genome-wide association study identifies variants in the ABO locus associated with susceptibility to pancreatic cancer

Laufey Amundadottir, Peter Kraft, Rachael Z. Stolzenberg-Solomon, Charles S. Fuchs, Gloria M. Petersen, Alan A. Arslan, H. Bas Bueno-De-Mesquita, Myron Gross, Kathy Helzlsouer, Eric J. Jacobs, Andrea LaCroix, Wei Zheng, Demetrius Albanes, William Bamlet, Christine D. Berg, Franco Berrino, Sheila Bingham, Julie E. Buring, Paige M. Bracci, Federico CanzianFrançoise Clavel-Chapelon, Sandra Clipp, Michelle Cotterchio, Mariza De Andrade, Eric J. Duell, John W. Fox, Steven Gallinger, J. Michael Gaziano, Edward L. Giovannucci, Michael Goggins, Carlos A. González, Göran Hallmans, Susan E. Hankinson, Manal Hassan, Elizabeth A. Holly, David J. Hunter, Amy Hutchinson, Rebecca Jackson, Kevin B. Jacobs, Mazda Jenab, Rudolf Kaaks, Alison P. Klein, Charles Kooperberg, Robert C. Kurtz, Donghui Li, Shannon M. Lynch, Margaret Mandelson, Robert R. McWilliams, Julie B. Mendelsohn, Dominique S. Michaud, Sara H. Olson, Kim Overvad, Alpa V. Patel, Petra H.M. Peeters, Aleksandar Rajkovic, Elio Riboli, Harvey A. Risch, Xiao Ou Shu, Gilles Thomas, Geoffrey S. Tobias, Dimitrios Trichopoulos, Stephen K. Van Den Eeden, Jarmo Virtamo, Jean Wactawski-Wende, Brian M. Wolpin, Herbert Yu, Kai Yu, Anne Zeleniuch-Jacquotte, Stephen J. Chanock, Patricia Hartge, Robert N. Hoover

Research output: Contribution to journal › Article › peer-review

438 Scopus citations

Abstract

We conducted a two-stage genome-wide association study of pancreatic cancer, a cancer with one of the lowest survival rates worldwide. We genotyped 558,542 SNPs in 1,896 individuals with pancreatic cancer and 1,939 controls drawn from 12 prospective cohorts plus one hospital-based case-control study. We conducted a combined analysis of these groups plus an additional 2,457 affected individuals and 2,654 controls from eight case-control studies, adjusting for study, sex, ancestry and five principal components. We identified an association between a locus on 9q34 and pancreatic cancer marked by the SNP rs505922 (combined P = 5.37 × 10^-8; multiplicative per-allele odds ratio 1.20; 95% confidence interval 1.12-1.28). This SNP maps to the first intron of the ABO blood group gene. Our results are consistent with earlier epidemiologic evidence suggesting that people with blood group O may have a lower risk of pancreatic cancer than those with groups A or B.

Original language	English (US)
Pages (from-to)	986-990
Number of pages	5
Journal	Nature Genetics
Volume	41
Issue number	9
DOIs	https://doi.org/10.1038/ng.429
State	Published - Sep 2009

ASJC Scopus subject areas

Genetics

Access to Document

10.1038/ng.429

Cite this

Amundadottir, L., Kraft, P., Stolzenberg-Solomon, R. Z., Fuchs, C. S., Petersen, G. M., Arslan, A. A., Bueno-De-Mesquita, H. B., Gross, M., Helzlsouer, K., Jacobs, E. J., LaCroix, A., Zheng, W., Albanes, D., Bamlet, W., Berg, C. D., Berrino, F., Bingham, S., Buring, J. E., Bracci, P. M., ... Hoover, R. N. (2009). Genome-wide association study identifies variants in the ABO locus associated with susceptibility to pancreatic cancer. Nature Genetics, 41(9), 986-990. https://doi.org/10.1038/ng.429

Amundadottir, L, Kraft, P, Stolzenberg-Solomon, RZ, Fuchs, CS, Petersen, GM, Arslan, AA, Bueno-De-Mesquita, HB, Gross, M, Helzlsouer, K, Jacobs, EJ, LaCroix, A, Zheng, W, Albanes, D, Bamlet, W, Berg, CD, Berrino, F, Bingham, S, Buring, JE, Bracci, PM, Canzian, F, Clavel-Chapelon, F, Clipp, S, Cotterchio, M, De Andrade, M, Duell, EJ, Fox, JW, Gallinger, S, Gaziano, JM, Giovannucci, EL, Goggins, M, González, CA, Hallmans, G, Hankinson, SE, Hassan, M, Holly, EA, Hunter, DJ, Hutchinson, A, Jackson, R, Jacobs, KB, Jenab, M, Kaaks, R, Klein, AP, Kooperberg, C, Kurtz, RC, Li, D, Lynch, SM, Mandelson, M, McWilliams, RR, Mendelsohn, JB, Michaud, DS, Olson, SH, Overvad, K, Patel, AV, Peeters, PHM, Rajkovic, A, Riboli, E, Risch, HA, Shu, XO, Thomas, G, Tobias, GS, Trichopoulos, D, Van Den Eeden, SK, Virtamo, J, Wactawski-Wende, J, Wolpin, BM, Yu, H, Yu, K, Zeleniuch-Jacquotte, A, Chanock, SJ, Hartge, P & Hoover, RN 2009, 'Genome-wide association study identifies variants in the ABO locus associated with susceptibility to pancreatic cancer', Nature Genetics, vol. 41, no. 9, pp. 986-990. https://doi.org/10.1038/ng.429

@article{73637d86dcbd4624b84a42d44b0c515a,

title = "Genome-wide association study identifies variants in the ABO locus associated with susceptibility to pancreatic cancer",

abstract = "We conducted a two-stage genome-wide association study of pancreatic cancer, a cancer with one of the lowest survival rates worldwide. We genotyped 558,542 SNPs in 1,896 individuals with pancreatic cancer and 1,939 controls drawn from 12 prospective cohorts plus one hospital-based case-control study. We conducted a combined analysis of these groups plus an additional 2,457 affected individuals and 2,654 controls from eight case-control studies, adjusting for study, sex, ancestry and five principal components. We identified an association between a locus on 9q34 and pancreatic cancer marked by the SNP rs505922 (combined P = 5.37 × 10-8; multiplicative per-allele odds ratio 1.20; 95% confidence interval 1.12-1.28). This SNP maps to the first intron of the ABO blood group gene. Our results are consistent with earlier epidemiologic evidence suggesting that people with blood group O may have a lower risk of pancreatic cancer than those with groups A or B.",

author = "Laufey Amundadottir and Peter Kraft and Stolzenberg-Solomon, {Rachael Z.} and Fuchs, {Charles S.} and Petersen, {Gloria M.} and Arslan, {Alan A.} and Bueno-De-Mesquita, {H. Bas} and Myron Gross and Kathy Helzlsouer and Jacobs, {Eric J.} and Andrea LaCroix and Wei Zheng and Demetrius Albanes and William Bamlet and Berg, {Christine D.} and Franco Berrino and Sheila Bingham and Buring, {Julie E.} and Bracci, {Paige M.} and Federico Canzian and Fran{\c c}oise Clavel-Chapelon and Sandra Clipp and Michelle Cotterchio and {De Andrade}, Mariza and Duell, {Eric J.} and Fox, {John W.} and Steven Gallinger and Gaziano, {J. Michael} and Giovannucci, {Edward L.} and Michael Goggins and Gonz{\'a}lez, {Carlos A.} and G{\"o}ran Hallmans and Hankinson, {Susan E.} and Manal Hassan and Holly, {Elizabeth A.} and Hunter, {David J.} and Amy Hutchinson and Rebecca Jackson and Jacobs, {Kevin B.} and Mazda Jenab and Rudolf Kaaks and Klein, {Alison P.} and Charles Kooperberg and Kurtz, {Robert C.} and Donghui Li and Lynch, {Shannon M.} and Margaret Mandelson and McWilliams, {Robert R.} and Mendelsohn, {Julie B.} and Michaud, {Dominique S.} and Olson, {Sara H.} and Kim Overvad and Patel, {Alpa V.} and Peeters, {Petra H.M.} and Aleksandar Rajkovic and Elio Riboli and Risch, {Harvey A.} and Shu, {Xiao Ou} and Gilles Thomas and Tobias, {Geoffrey S.} and Dimitrios Trichopoulos and {Van Den Eeden}, {Stephen K.} and Jarmo Virtamo and Jean Wactawski-Wende and Wolpin, {Brian M.} and Herbert Yu and Kai Yu and Anne Zeleniuch-Jacquotte and Chanock, {Stephen J.} and Patricia Hartge and Hoover, {Robert N.}",

note = "Funding Information: 34Department of Public Health and Clinical Medicine, Nutritional Research, Ume{\aa} University, Ume{\aa}, Sweden. 35Department of Gastrointestinal Medical Oncology, University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA. 36Core Genotyping Facility, Advanced Technology Program, SAIC-Frederick, Inc., NCI-Frederick, Frederick, Maryland, USA. 37Division of Endocrinology, Diabetes and Metabolism, Department of Internal Medicine and Center for Clinical and Translational Science, Ohio State University, Columbus, Ohio, USA. 38Bioinformed, LLC, Gaithersburg, Maryland, USA. 39Department of Oncology, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. 40Department of Epidemiology, The Johns Hopkins Bloomberg School of Public Health, The Sol Goldman Pancreatic Research Center, The Johns Hopkins Medical Institutions, Baltimore, Maryland, USA. 41Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York, USA. 42Epidemiology and Genetics Research Program, Division of Cancer Control and Population Sciences, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland, USA. 43Group Health Center for Health Studies, Seattle, Washington, USA. 44Department of Oncology, College of Medicine, Mayo Clinic, Rochester, Minnesota, USA. 45Division of Epidemiology, Public Health and Primary Care, Imperial College London, London, UK. 46Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, New York, USA. 47Department of Cardiology and Department of Clinical Epidemiology, Aalborg Hospital, Aarhus University Hospital, Aalborg, Denmark. 48Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands. 49Department of Obstetrics and Gynecology, Baylor College of Medicine, Houston, Texas, USA. 50Yale University School of Public Health, New Haven, Connecticut, USA. 51Department of Hygiene and Epidemiology, University of Athens Medical School, Athens, Greece. 52Division of Research, Kaiser Permanente, Northern California Region, Oakland, California, USA. 53Department of Chronic Disease Prevention, National Institute for Health and Welfare, Helsinki, Finland. 54Department of Social and Preventive Medicine, University at Buffalo, State University of New York, Buffalo, New York, USA. 55These authors contributed equally to this work. Correspondence should be addressed to S.J.C. (chanocks@mail.nih.gov). Funding Information: Study participants. Participants in stage 1 of the GWAS were drawn from 12 cohort studies and one case-control study (Supplementary Table 1) in the Pancreatic Cancer Cohort Consortium Genome-Wide Association Study (Pan-Scan1) and are part of a larger international consortium, the National Cancer Institute–sponsored Cohort Consortium. They include the Alpha-Tocopherol Beta-Carotene Cancer Prevention Study (ATBC)8, CLUE II (ref. 10), the American Cancer Society Cancer Prevention Study II (CPS-II)7, the European Prospective Investigation into Cancer and Nutrition (EPIC, comprising cohorts from Denmark, France, Germany, the UK, Greece, Italy, the Netherlands, Spain and Sweden)9, the Health Professionals Follow-up Study (HPFS)11, Nurses{\textquoteright} Health Study (NHS)11, the New York University Women{\textquoteright}s Health Study (NYUWHS)12, the Physicians{\textquoteright} Health Study I (PHS I)11, the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO)13, the Shanghai Men{\textquoteright}s and Women{\textquoteright}s Health Study (SMWHS)14,15, the Women{\textquoteright}s Health Initiative (WHI)16, and the Women{\textquoteright}s Health Study (WHS)17. Each cohort that participated in PanScan had a defined population from whom blood or buccal cells were collected before the diagnosis of pancreatic cancer. Incident primary pancreatic adenocarcinoma cases were identified by self-report with subsequent medical record review, linkage with a cancer registry or both. Cases were defined as primary adenocarcinoma of the exocrine pancreas (ICD-O-3 code C250–C259). Non-exocrine pancreatic tumors (histology type 8150, 8151, 8153, 8155 and 8240) were excluded.",

year = "2009",

month = sep,

doi = "10.1038/ng.429",

language = "English (US)",

volume = "41",

pages = "986--990",

journal = "Nature Genetics",

issn = "1061-4036",

publisher = "Nature Publishing Group",

number = "9",

}

TY - JOUR

T1 - Genome-wide association study identifies variants in the ABO locus associated with susceptibility to pancreatic cancer

AU - Amundadottir, Laufey

AU - Kraft, Peter

AU - Stolzenberg-Solomon, Rachael Z.

AU - Fuchs, Charles S.

AU - Petersen, Gloria M.

AU - Arslan, Alan A.

AU - Bueno-De-Mesquita, H. Bas

AU - Gross, Myron

AU - Helzlsouer, Kathy

AU - Jacobs, Eric J.

AU - LaCroix, Andrea

AU - Zheng, Wei

AU - Albanes, Demetrius

AU - Bamlet, William

AU - Berg, Christine D.

AU - Berrino, Franco

AU - Bingham, Sheila

AU - Buring, Julie E.

AU - Bracci, Paige M.

AU - Canzian, Federico

AU - Clavel-Chapelon, Françoise

AU - Clipp, Sandra

AU - Cotterchio, Michelle

AU - De Andrade, Mariza

AU - Duell, Eric J.

AU - Fox, John W.

AU - Gallinger, Steven

AU - Gaziano, J. Michael

AU - Giovannucci, Edward L.

AU - Goggins, Michael

AU - González, Carlos A.

AU - Hallmans, Göran

AU - Hankinson, Susan E.

AU - Hassan, Manal

AU - Holly, Elizabeth A.

AU - Hunter, David J.

AU - Hutchinson, Amy

AU - Jackson, Rebecca

AU - Jacobs, Kevin B.

AU - Jenab, Mazda

AU - Kaaks, Rudolf

AU - Klein, Alison P.

AU - Kooperberg, Charles

AU - Kurtz, Robert C.

AU - Li, Donghui

AU - Lynch, Shannon M.

AU - Mandelson, Margaret

AU - McWilliams, Robert R.

AU - Mendelsohn, Julie B.

AU - Michaud, Dominique S.

AU - Olson, Sara H.

AU - Overvad, Kim

AU - Patel, Alpa V.

AU - Peeters, Petra H.M.

AU - Rajkovic, Aleksandar

AU - Riboli, Elio

AU - Risch, Harvey A.

AU - Shu, Xiao Ou

AU - Thomas, Gilles

AU - Tobias, Geoffrey S.

AU - Trichopoulos, Dimitrios

AU - Van Den Eeden, Stephen K.

AU - Virtamo, Jarmo

AU - Wactawski-Wende, Jean

AU - Wolpin, Brian M.

AU - Yu, Herbert

AU - Yu, Kai

AU - Zeleniuch-Jacquotte, Anne

AU - Chanock, Stephen J.

AU - Hartge, Patricia

AU - Hoover, Robert N.

N1 - Funding Information: 34Department of Public Health and Clinical Medicine, Nutritional Research, Umeå University, Umeå, Sweden. 35Department of Gastrointestinal Medical Oncology, University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA. 36Core Genotyping Facility, Advanced Technology Program, SAIC-Frederick, Inc., NCI-Frederick, Frederick, Maryland, USA. 37Division of Endocrinology, Diabetes and Metabolism, Department of Internal Medicine and Center for Clinical and Translational Science, Ohio State University, Columbus, Ohio, USA. 38Bioinformed, LLC, Gaithersburg, Maryland, USA. 39Department of Oncology, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. 40Department of Epidemiology, The Johns Hopkins Bloomberg School of Public Health, The Sol Goldman Pancreatic Research Center, The Johns Hopkins Medical Institutions, Baltimore, Maryland, USA. 41Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York, USA. 42Epidemiology and Genetics Research Program, Division of Cancer Control and Population Sciences, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland, USA. 43Group Health Center for Health Studies, Seattle, Washington, USA. 44Department of Oncology, College of Medicine, Mayo Clinic, Rochester, Minnesota, USA. 45Division of Epidemiology, Public Health and Primary Care, Imperial College London, London, UK. 46Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, New York, USA. 47Department of Cardiology and Department of Clinical Epidemiology, Aalborg Hospital, Aarhus University Hospital, Aalborg, Denmark. 48Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands. 49Department of Obstetrics and Gynecology, Baylor College of Medicine, Houston, Texas, USA. 50Yale University School of Public Health, New Haven, Connecticut, USA. 51Department of Hygiene and Epidemiology, University of Athens Medical School, Athens, Greece. 52Division of Research, Kaiser Permanente, Northern California Region, Oakland, California, USA. 53Department of Chronic Disease Prevention, National Institute for Health and Welfare, Helsinki, Finland. 54Department of Social and Preventive Medicine, University at Buffalo, State University of New York, Buffalo, New York, USA. 55These authors contributed equally to this work. Correspondence should be addressed to S.J.C. (chanocks@mail.nih.gov). Funding Information: Study participants. Participants in stage 1 of the GWAS were drawn from 12 cohort studies and one case-control study (Supplementary Table 1) in the Pancreatic Cancer Cohort Consortium Genome-Wide Association Study (Pan-Scan1) and are part of a larger international consortium, the National Cancer Institute–sponsored Cohort Consortium. They include the Alpha-Tocopherol Beta-Carotene Cancer Prevention Study (ATBC)8, CLUE II (ref. 10), the American Cancer Society Cancer Prevention Study II (CPS-II)7, the European Prospective Investigation into Cancer and Nutrition (EPIC, comprising cohorts from Denmark, France, Germany, the UK, Greece, Italy, the Netherlands, Spain and Sweden)9, the Health Professionals Follow-up Study (HPFS)11, Nurses’ Health Study (NHS)11, the New York University Women’s Health Study (NYUWHS)12, the Physicians’ Health Study I (PHS I)11, the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO)13, the Shanghai Men’s and Women’s Health Study (SMWHS)14,15, the Women’s Health Initiative (WHI)16, and the Women’s Health Study (WHS)17. Each cohort that participated in PanScan had a defined population from whom blood or buccal cells were collected before the diagnosis of pancreatic cancer. Incident primary pancreatic adenocarcinoma cases were identified by self-report with subsequent medical record review, linkage with a cancer registry or both. Cases were defined as primary adenocarcinoma of the exocrine pancreas (ICD-O-3 code C250–C259). Non-exocrine pancreatic tumors (histology type 8150, 8151, 8153, 8155 and 8240) were excluded.

PY - 2009/9

Y1 - 2009/9

N2 - We conducted a two-stage genome-wide association study of pancreatic cancer, a cancer with one of the lowest survival rates worldwide. We genotyped 558,542 SNPs in 1,896 individuals with pancreatic cancer and 1,939 controls drawn from 12 prospective cohorts plus one hospital-based case-control study. We conducted a combined analysis of these groups plus an additional 2,457 affected individuals and 2,654 controls from eight case-control studies, adjusting for study, sex, ancestry and five principal components. We identified an association between a locus on 9q34 and pancreatic cancer marked by the SNP rs505922 (combined P = 5.37 × 10-8; multiplicative per-allele odds ratio 1.20; 95% confidence interval 1.12-1.28). This SNP maps to the first intron of the ABO blood group gene. Our results are consistent with earlier epidemiologic evidence suggesting that people with blood group O may have a lower risk of pancreatic cancer than those with groups A or B.

AB - We conducted a two-stage genome-wide association study of pancreatic cancer, a cancer with one of the lowest survival rates worldwide. We genotyped 558,542 SNPs in 1,896 individuals with pancreatic cancer and 1,939 controls drawn from 12 prospective cohorts plus one hospital-based case-control study. We conducted a combined analysis of these groups plus an additional 2,457 affected individuals and 2,654 controls from eight case-control studies, adjusting for study, sex, ancestry and five principal components. We identified an association between a locus on 9q34 and pancreatic cancer marked by the SNP rs505922 (combined P = 5.37 × 10-8; multiplicative per-allele odds ratio 1.20; 95% confidence interval 1.12-1.28). This SNP maps to the first intron of the ABO blood group gene. Our results are consistent with earlier epidemiologic evidence suggesting that people with blood group O may have a lower risk of pancreatic cancer than those with groups A or B.

UR - http://www.scopus.com/inward/record.url?scp=69349097813&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=69349097813&partnerID=8YFLogxK

U2 - 10.1038/ng.429

DO - 10.1038/ng.429

M3 - Article

C2 - 19648918

AN - SCOPUS:69349097813

SN - 1061-4036

VL - 41

SP - 986

EP - 990

JO - Nature Genetics

JF - Nature Genetics

IS - 9

ER -

Genome-wide association study identifies variants in the ABO locus associated with susceptibility to pancreatic cancer

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this